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INTRODUCTION 
• The proportion of cardiovascular disease (CVD) in the structure 
of mortality is about 56% of all cases, of which almost 90% of 
cases take death from coronary heart disease (CHD)
• Hypertension is often associated with CHD as a major cause of 
left ventricular hypertrophy and diffuse myocardiosclerosis -
remodeling of the heart muscle, which in turn contributes to 
different, sometimes fatal, arrhythmias and conduction disorders 
of the heart.
• Obesity - the most common metabolic disease, which is one of 
the important risk factor of developing CVD.
• Implantation of a permanent pacemaker is effective method of 
treatment resistant to medical therapy life-threatening cardiac 
arrhythmias and bradysystiolic arrhythmia, however, it does not 
eliminate the problem of support. AH is one of the most 
important clinical syndromes requiring therapeutic support. 
• AV-block is the most common indication for the implantation of 
pacemaker
T. Derienko CLINICAL FEATURES OF PATIENTS WITH PERMANENT PACEMAKERS DEPENDING ON THE 
STAGE OF ARTERIAL HYPERTENSION/T. Derienko, D. Volkov// The Journal of V. N. Karazin Kharkiv National 
University, series "Medicine. -2015. - №30- p.5-8
OUR PATIENT
• Male
• Age:55 y.o.
• Factory Worker
• Townsman
• Admitted to our polyclinic 10/12/2016
COMPLAINTS
• Dyspnea, during physical activity, absent at rest
• Fatigue
• Chest pain, behind the breastbone during physical 
activity(400m)
MEDICAL HISTORY 1.1
• 1978 – myocarditis(not confirmed by medical records), then 
diagnosed full right bundle branch block.
• 2011 – hypertension (max 170/100 mmHg, usual BP 140/90 
mmHg(with drugs))
• 2011 – chest pain behind the breastbone during ordinary  physical 
activity absent at rest (refused to do coronary angiography)
• 2011 – during stress test first diagnosed transient atrioventricular
block stage 2  Mobitz II
• 2014 – atherosclerosis of coronary arteries
• Sinse 2014 diagnosis: IHD:STABLE ANGINA.AH II STAGE, 2 
DEGREE. FULL RBBB. TRANSIENT AV BLOCK STAGE 2, MOBITZ 
2. HF I.
• 2005 - peptic ulcer disease and GERD
MEDICAL HISTORY 1.2
STRESS TEST ECG X/X/2011
Conclusion:transient AV block stage 2 Mobiz 2
MEDICAL HISTORY 1.3
CORONARY ANGIOGRAPHY 17/04/2014
Conclusion:Right descending artery atherosclerosis 20-30%, 
atherosclerotic plaque mouth diagonal artery 40%, atherosclerotic lesions 
of the circumflex artery and the right coronary artery 20-30%
MEDICAL HISTORY 2.2
26/10/2015 – during usual physical activity felt dizziness, weakness, 
tinnitus, nausea, loss of consciousness was not noted, on the ECG 
recorded complete atrioventricular block.
Conclusion: 
rhytm regular, 
heart rate 
35bpm , signs 
of left 
ventricular
hypertrophy, 
full RBBB,  
transient AV-
block 3 
degree.
INDICATIONS FOR THE 
IMPLANTATION OF CARDIAC 
PACEMAKER 
Class I
1. Third-degree AV block at any anatomic level associated with any one of the 
following conditions: 
a. Bradycardia with symptoms presumed to be due to AV block. (Level of 
evidence: C)
b. Arrhythmias and other medical conditions that require drugs that result in 
symptomatic bradycardia. (Level of evidence: C)
c. Documented periods of asystole ≥3.0 seconds or any escape rate <40 beats per 
minute (bpm) in awake, symptom-free patients. (Level of evidence: B, C)
d. After catheter ablation of the AV junction. (Level of evidence: B, C) There are no 
trials to assess outcome without pacing, and pacing is virtually always planned in 
this situation unless the operative procedure is AV junction modification. 
e. Postoperative AV block that is not expected to resolve. (Level of evidence: C)
f. Neuromuscular diseases with AV block such as myotonic muscular dystrophy, 
Kearns-Sayre syndrome, Erb’s dystrophy (limb-girdle), and peroneal muscular 
atrophy. (Level of evidence: B)
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
/ [M. Brignole, A. Auricchio, B. Gonzalo et.al.]. // European Heart Journal. – 2013..
MEDICAL HISTORY 2.3
27/10/15 – ESPRITE DDR (Dual Chamber Ventricular  
pacemaker), mode of stimulation DDD:
• HR-60bpm, stimulation threshold-0,75V, impedance-350Om
Conclusion: sinus rhythm, regular, heart rate 76bpm , full RBBB, 
signs of left ventricular hypertrophy
PATIENT’S MEDICAL 
TREATMENT FOR THE 
LAST YEAR
• Perindopril 4 mg
• Amlodipin 5 mg
• Atorvastatin 40 mg
• Aspirin 75 mg
LIFE/SOCIAL HISTORY
• Married
• Smoking History: 15 Pack years (1/2 pack for 30 years)(quit 
smoking two years ago)
• Father died from ventricular rupture. 
• Mother died from stroke secondary to Long standing 
hypertension
OBJECTIVE SUBJECT 1.2.
• The general condition is satisfactory, consciousness is clear, 
emotionally stable, optimistic mood
• Hypersthenic, Height = 176 cm, Weight = 115 kg, BMI= 37.1 
(Obese)
• Skin, visible mucous membranes are pale pink and
clean
• Peripheral lymph nodes are not palpable
• The thyroid is not palpable 
• Signs of eyelid retraction, periorbital edema, proptosis are absent
OBJECTIVE SUBJECT 2.2.
 Respiratory System:
• pulmonary percussion –normal
• auscultation - weakened vesicular breathing, no adventitious sounds
 Cardiovascular system:
• heart borders extended to the left on 1,5 cm of mid clavicular line, HR 
=78 bpm, regular.
• no pulse deficiency; heart sounds are muted
 Blood Pressure left hand = 145/100 mmHg (on the background of 
antihypertensive therapy), Blood Pressure of right hand = 140/90 
mmHg
 Gastrointestinal system:
• abdomen is soft, painless, symmetrical, no discrepancies of the 
abdominal muscles, no visible peristalsis
• liver edge is smooth, painless , palpated 0.5 cm below the costal arch
spleen and pancreas are not palpable
PRESCRIBED EXAMINATIONS
 Complete blood test
 General urine test
 Biochemical blood test 
 Liver function test (ALT, AST, AP)
 Blood lipid spectrum
 ECG
 Echocardiogram
COMPLETE BLOOD COUNT 
10/12/2016
INDEX RESULT NORMAL
Erythrocyte 4.23 3.9-4.7
Hematocrit 41.1% 36-42%
Hemoglobin 135 g/l 120-140g/l
Thrombocyte 313 g/l 160-320 g/l
Leukocyte 7.7 g/l 4-9.0 g/l
Lymphocyte 22% 19-37%
ESR 3 mm/hr 2-15 mm/hr
Conclusion: normal
URINALYSIS 10/12/2016
INDEX RESULT NORMAL
Specific Gravity 1.011 1.000 – 1.030
Glucose Negative Negative
Protein Negative Negative
Leucocyte 4.7 0-5 WBC/hpf
Conclusion: normal
BIOCHEMICAL BLOOD TEST 
10/12/2016
INDEX RESULT NORMAL
Bilirubin 15.6 μmol/l 2-20 μmol/l
Creatinine 113 μmol/l 60-123 μmol/l
Urea 6 μmol/l 2.5-7 μmol/l
Blood Sugar 5.8 μmol/l ≤ 6.1 μmol/l
AST 30 8-38 U/L
ALT 38 8-40 U/L
Conclusion: normal
BLOOD LIPID SPECTRUM
10/12/2016
INDEX RESULT NORMAL
Cholesterol 4.65 < 5.2 mmol/l
VLDL 0.6120 < 1.0 mmol/l
LDL 2.9680 < 3.5 mmol/l
HDL 1.07 > 0.9 mmol/l
Triglycerides 1.36 ≤ 2.3 mmol/l
Conclusion: normal
ECHOCARDIOGRAPHY 1.1
INDEX RESULT NORMAL
Aorta 36.0 20-37mm
Aortic valve 19.0 17-26mm
Mitral valve 32.0 26-35mm
Left atrium 33.0mm To 38 mm
End Diastolic velocity 100 50-180 cm/s
End Systolic volume 50.0 35-55mm
Left Ventricular 14.1 6-11mm
Ejection Fraction 69% 55-78%
Left Ventricule amplitude 9.9 mm 7-13mm
Intraventricular septum 13.0 mm 6-11mm
Right atrial diameter 34.0mm ≤45mm
Right Ventricular diameter 23.0 mm 9-26mm
Conclusion:Atherosclerosis of aorta and
aortic valves mild degree,hypertrophy of the left ventricle. Dyssynergic
areas were not identified.
BASIC CLINICAL 
SYNDROMES
• Atherosclerosis (sclerotic changes of aorta and aortic valve)
• Ischemia (Stable Angina)
• Arterial hypertension
• Conduct disorder
• Heart failure
• Obesity
• Duodenum Ulcer (2005)
THE CLINICAL 
DIAGNOSIS
ACCORDING
TO CURRENT 
CLASSIFICATIONS
CLASSIFICATION OF CHD
(ON THE RECOMMENDATIONS OF THE EUROPEAN SOCIETY OF CARDIOLOGY ESC, 2013)
2. Angina
2.1.1. Stable angina (indicating the functional classes (FC).
2.1.2. Stable angina with angiographically intact vessels (coronary 
syndrome X).
2.2. Vazospastichna angina (angiospastic, spontaneous, variant, 
Printsmetalla).
2.3 Mixed angina
2.4 Unstable angina (up to 28 days)
2.4.1. Angina, which appeared for the first time to 28 days (angina 
that occurred for the first time, with transient ECG changes - rest).
2.4.2. Progressive angina (angina at rest or the appearance of 
night attacks in a patient with angina pectoris, angina change, 
progressive decrease in exercise
tolerance, transient ECG changes - rest).
2.3.3. Early post-infarction angina (from 3 to 28 days).
CLASSIFICATION OF 
HYPERTENSION ACCORDING TO 
THE LEVEL OF BLOOD PRESSURE
(RECOMMENDATIONS BY THE UKRAINIAN ASSOCIATION OF CARDIOLOGISTS 
PREVENTION AND
TREATMENT OF HYPERTENSION, 2008)
DiastolicSystolicCategory
<80and<120Optimal
80-84and/or120-129Normal
85-89and/or130-139High normal
90-99and/or140-159Grade 1 hypertension
100-109and/or160-179Grade 2 hypertension
>110and/or>180Grade 3 hypertension
<90or>140Isolated systolic 
hypertension
http://emedicine.medscape.com/article/241381-overview
CLASSIFICATION OF HYPERTENSION 
STAGES 
(RECOMMENDATIONS OF THE ASSOCIATION OF CARDIOLOGISTS OF UKRAINE 2008)
Stage The degree of target organ damage
I Objective changes in the target organs are absent
II There is objective evidence of target organ damage without symptoms with 
their hand or dysfunction:Left ventricular hypertrophy (on ECG, ultrasound, 
Ro)
Generalized narrowing of retinal arteries Microalbuminuria and / or a small 
increase
in serum creatinine (y m. - 115 - 133 mmol / L at x. -107 - 124 mmol / l) Carotid 
artery disease - a thickening of the intima-media> 0.9 mm or the presence of 
atherosclerotic plaques.
III There is objective evidence of target organ damage with symptoms from their 
side and impaired heart - myocardial infarction, heart failure II A - III stage;
brain - stroke, transient ischemic attack, acute hypertensive encephalopathy,
vascular dementia; fundus - hemorrhage and retinal exudates with 
papilledema the optic nerve or without;
kidney - concentration of plasma creatinine in males> 133 umol / L, y Women> 
124;
vessels - dissecting aortic aneurysm; peripheral arterial occlusion
http://www.mif-ua.com/education/symposium/arterialnaya-gipertenziya-v-2014-g-klassifikacii-
diagnostika-lechenie#test_end
HYPERTENSION RISK FACTORS 
http://www.brainandspine.com.hk/en/stroke/stroke-in-depth
CARDIOVASCULAR RISK STRATIFICATION 
CHART WITH RECOMMENDED FOLLOW-UP 
FREQUENCY FOR EACH CATEGORY
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration withEACTS
THE NEW YORK HEART ASSOCIATION 
(NYHA)FUNCTIONAL CLASSIFICATION 
(FUNCTIONAL CAPACITY)
OF CHRONIC HEART FAILURE
http://www.intechopen.com/books/primary-care-in-practice-integration-is-needed/integrated-care-for-heart-
failure-in-primary-care
AMERICAN HEART ASSOCIATION
HEART FAILURE STAGES
Class Objective Assessment
A No objective evidence of cardiovascular disease. No symptoms 
and no limitation in ordinary physical activity.
B Slight limitation of physical activity. Comfortable at rest. Ordinary 
physical activity results in fatigue, palpitation, dyspnea (shortness 
of breath).
C Objective evidence of moderately severe cardiovascular disease. 
Marked
limitation in activity due to symptoms, even during less-than-
ordinary activity.Comfortable only at rest.
D Objective evidence of severe cardiovascular disease. Severe 
limitations.Experiences symptoms even while at rest.
http://www.sunshineheart.com/patients/classification-of-heart-failure
DEFINITION OF HEART FAILURE WITH 
PRESERVED (HFPEF),MID-RANGE 
(HFMREF) AND REDUCED EJECTION 
FRACTION (HFREF)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
CLASSIFICATION OF OVERWEIGHT 
AND OBESITY BMI CLASSIFICATION
Classification BMI Category
(kg/m2)
Risk of developing
health problems
Underweight <18.5 Increased
Normal Weight 18.5 - 24.9 Least
Overweight 25.0 - 29.9 Increased
Obese class I 30.0 - 34.9 High
Obese class II 35.0 - 39.9 Very high
Obese class III >= 40.0 Extremely high
http://www.hc-sc.gc.ca/fn-an/nutrition/weights-poids/guide-ld-adult/bmi_chart_java-graph_imc_java-eng.php
COMPLETE MAIN DIAGNOSIS OF 
OUR PATIENT
 Ischemic heart disease
 Stable angina, II FC
 Essential arterial hypertension II stage, 2 degree, hypertensive 
heart (LVH)
 Full RBBB
 Full AV-block
 Condition after the implantation of cardiac pacemaker ESPRIT 
DR, mode of stimulation DDD
 Heart failure with preserved ejection fraction, II FC, stage B
CO-MORBIDITY OF OUR PATIENT
 Obesity II class
 Peptic ulcer disease and GERD
TREATMENT
LIFESTYLE 
MODIFICATION
 Intensive weight reduction
 DASH diet
 Control of compliance to medical 
recommendations
PHARMACOLOGICAL TREATMENT 
IN STABLE FORMS OF IHD
http://eurheartj.oxfordjournals.org/content/ehj/34/38/2949.full.pdf
SUMMARY OF RECOMMENDATIONS 
AND TREATMENT STRATEGIES IN 
PATIENTS WITH AH
2013 ESH/ESC Guidelines for themanagement of arterial hypertension
SUMMARY OF RECOMMENDATIONS ON 
THERAPEUTIC STRATEGIES IN 
HYPERTENSIVE PATIENTS WITH HEART
DISEASE
2013 ESH/ESC Guidelines for themanagement of arterial hypertension
RECOMMENDATIONS FOR TREATMENT 
OF PATIENTS WITH HEART FAILURE WITH 
PRESERVED EJECTION FRACTION
http://eurheartj.oxfordjournals.org/content/37/27/2129
OUR RECOMMENDED 
TREATMENT
 Β-blocker: bisoprolol 5 mg in the morning
 ACE-inhibitor: enalapril 5 mg in the evening
 Statin: rosuvastatin 20 mg in the evening
PROGNOSIS
▶ Prognosis for life - non-compliance to doctor's 
appointments – non-satisfactory
▶ The prognosis for recovery – an unfavorable
CONCLUSIONS
 Cardiac pacing in the presence of possible solutions to the 
problem of arrhythmias and HF it does not cancel, but modifies 
the medical support of patients
 Reliability and quality of modern devices that are based on 
science and technology, gives confidence to physicians and 
patients that the number of people who live fully life with 
pacemaker (ECS) will continue to grow up.
Ponomarenko V. B. Results of treatment in patients with atrioventricular blockade (retrospective 
data analysis)/V. B. Ponomarenko. Vestnik Arrhythmology. -2001. -№ 22. -P. 5-12
